{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-164853","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.060409+00:00","generated_at":"2026-05-18T01:14:16.492059+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share","bullets":["Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.","Milestone closing option for another ~$50M upon LYL314 PiNACLE trial milestone within 12 months.","Investor call option to purchase additional shares at $30.73/share before milestone closing.","Proceeds to fund two pivotal-stage trials of LYL314 and extend cash runway into mid-2027.","Resale registration rights granted; securities issued in exempt private placement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-164853","json":"https://secwatch.observer/filing/0001193125-25-164853.json","markdown":"https://secwatch.observer/filing/0001193125-25-164853.md","text":"https://secwatch.observer/filing/0001193125-25-164853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525164853/0001193125-25-164853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525164853/d24368d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:14:16.492059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}